Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's LTM Mar 2026 gross profit of $0 is the 5th highest of the 11 companies compared; the peer median is -$7.6M.
ELDN Competitors Peer median
Gross Profit for ELDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$201.36M +7.0%-4.1%92.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$169.15M +0.4%-0.5%74.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$7.55M +1072.9%+64.5%51.9%
EDITEditas Medicine, Inc.LTM Mar 2026$2.25M +105.3%+44.7%5.8%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$111K ———
HUMAHumacyte, Inc.LTM Mar 2026-$15.09M -917.5%—748.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$31.63M +46.9%—86.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$34.31M -119.9%—598.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M -72.9%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M +23.8%——
Peer median (excluding ELDN) -$7.6M+7.0%+22.1%86.7%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.74M27.08M30.31M51.96M66.27M
Selling, General & Admin13.13M12.7M12.69M18.61M16.98M
Operating Expenses36.87M88.43M43M70.58M83.25M
Depreciation & Amortization195K373K374K359K313K
EBITDA(36.67M)(39.41M)(116.16M)(35.39M)(45.27M)
EBITDA Margin—————
Operating Income(36.87M)(88.43M)(43M)(70.58M)(83.25M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses7K462K(73.54M)34.82M37.67M
Income Before Tax(36.86M)(87.97M)(116.54M)(35.75M)(45.58M)
Pre-Tax Margin—————
Income Tax Expense(2.35M)00431K35K
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Net Margin—————
EPS (Basic)(2.33)(6.16)(4.73)(0.75)(0.56)
EPS (Diluted)(2.33)(6.16)(4.73)(0.75)(0.56)
Weighted Avg Shares14.82M14.29M24.62M48.54M81.84M
Weighted Avg Shares (Diluted)14.82M14.29M24.62M48.54M81.84M

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.